Date and Time: 12th November 2013 (10.00 – 3.30pm)

Minutes: confirmed

Guideline Development Group Meeting 4: Coeliac disease

Place: Prospero House, London SE1 1GA

Present:
- Damien Longson (Chair) (DL)
- Mohamed Abuzak (MA)
- Steph Briggs (SB)
- Martin Dadswell (MD)
- Berne Ferry (BF)
- Mike Forrest (MF)
- Peter Gillett (PG)
- Rajeev Gupta (RG)
- Anne Holdoway (AH)
- Norma McGough (NM)
- Simon Murch (SM)
- Gerry Robins (GR)
- David Sanders (DS)
- Rita Shergill-Bonner (RSB)
- Jeremy Woodward (JW)

Apologies:
- Sorrell Burden (SB)

In attendance:

<table>
<thead>
<tr>
<th>NICE Staff:</th>
<th>Apologies:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emma Banks (EB)</td>
<td>Michael Heath (MH)</td>
</tr>
<tr>
<td>Ben Doak (BD)</td>
<td>Gabriel Rogers (GR)</td>
</tr>
<tr>
<td>Sue Ellerby (SE)</td>
<td>Heather Stegenga (HS)</td>
</tr>
<tr>
<td>Liz Evans (LE)</td>
<td>Toni Tan (TT)</td>
</tr>
</tbody>
</table>

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Houten (RH)</td>
</tr>
</tbody>
</table>

Notes

1. DL welcomed the group to the 4th meeting of this GDG. Apologies were received from SB. Minutes for the previous meeting were agreed.

2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. AH declared a meeting that she was about to attend for which she would receive reimbursement. DL agreed this declaration should be noted but participation at this meeting would not be affected. No further conflicts of interest were declared by the group.
3. SE took the GDG through the revised protocol for the review question addressing the diagnosis of non-responsive and refractory coeliac disease. The group discussed areas such as their understanding of the terminology, population thresholds, date restrictions and the origin of studies to be included, subgroups for different age groups and different approaches taken in practice for children and adults.

4. HS presented the evidence for review question 1 with regards to populations with an increased risk of coeliac disease and the long-term consequences of undiagnosed or untreated coeliac disease. The GDG discussed some of the issues around the evidence base for these sections of the question and it was agreed these sections would be revisited at the next meeting having taken on board the groups input.

5. SE spoke to the group about the NICE pathways project and that the overall aim of the project is to enable users to search for related guidance more systematically and see the range of related topics more easily. SE then went onto share the first draft of the coeliac disease pathway to gain initial thoughts from the group. At the end of the demonstration SE explained next steps and how the GDG could help in the future.

6. EB reminded the group of the importance of declaring any new or potential conflicts of interest to the NICE team and Chair as soon as possible.

7. There were no further matters of business arising so DL drew to meeting to a close early, thanked all attendees for their input and confirmed the next meeting would be on the 18th December (10 – 4.30pm) at NICE offices, Manchester.